Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | KIF18A | Q8NI77 | 9/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | STK3 | Q13188 | 1/20 | 0.32 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SDHA | P31040 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20696784 | 1.00 | SOS1 (0.42) | SOS1KIF18AACACBELOVL1SYK | |
| SCHEMBL21245952 | 1.00 | SOS1 (0.42) | SOS1KIF18AACACBELOVL1SYK | |
| SCHEMBL20688189 | 0.87 | SOS1 (0.39) | SOS1KIF18AACACBELOVL1SYK | |
| SCHEMBL20688222 | 0.87 | SOS1 (0.39) | SOS1KIF18AACACBELOVL1SYK | |
| SCHEMBL21285288 | 0.84 | SOS1 (0.37) | SOS1KIF18AACACBELOVL1SYK | |
| SCHEMBL20688212 | 0.84 | SOS1 (0.37) | SOS1KIF18AACACBELOVL1SYK | |
| SCHEMBL20697004 | 0.83 | TYK2 (0.41) | KIF18AACACBTYK2TRPV3 | |
| SCHEMBL20689076 | 0.79 | GRIN2D (0.40) | SOS1KIF18AELOVL1PTGS1SDHA | |
| SCHEMBL13034794 | 0.78 | GAA (0.44) | KIF18AACACBCLK2GSK3AGSK3B | |
| SCHEMBL21245954 | 0.78 | TYK2 (0.46) | KIF18ATYK2TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SOS1 1189/4885KIF18A 1817/4885ACACB 2158/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SOS1 1189/4885KIF18A 1817/4885ACACB 2158/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SOS1 1189/4885KIF18A 1817/4885ACACB 2158/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SOS1 1189/4885KIF18A 1817/4885ACACB 2158/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SOS1 1189/4885KIF18A 1817/4885ACACB 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.